Outpatient parenteral antibiotic therapy: principles and practice.

Outpatient parenteral antimicrobial therapy (OPAT) refers to the administration of a parenteral antimicrobial in a non inpatient or ambulatory setting with the explicit aim of facilitating admission avoidance or early discharge. Whilst OPAT has predominantly been the domain of the infection specialist, the internal medicine specialist has a key role in service development and delivery as a component of broader ambulatory care initiatives such as "hospital at home". Main drivers for OPAT are patient welfare, reduction of risk of health care associated infection and cost-effective use of hospital resources. The safe practice of OPAT is dependent on a team approach with careful patient selection and antimicrobial management with programmed and adaptable clinical monitoring and assessment of outcome. Gram-positive infections, including cellulitis, bone and joint infection, bacteraemia and endocarditis are key infections potentially amenable to OPAT whilst resistant Gram-negative infections are of increasing importance. Ceftriaxone, teicoplanin, daptomycin and ertapenem lend themselves well to OPAT due to daily (or less frequent) bolus administration, although any antimicrobial may be administered if the patient is trained to administer and/or an appropriate infusion device is employed. Clinical experience from NHS Greater Glasgow and Clyde is presented to illustrate the key principles of OPAT as practised in the UK. Increasingly complex patients with multiple medical needs, the relative scarcity of inpatient resources and the broader challenge of ambulatory care and "hospital at home" will ensure the internal medicine specialist will have a key role in the future development of OPAT.

[1]  R. Seaton,et al.  Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service. , 2011, The Journal of antimicrobial chemotherapy.

[2]  J. Watson,et al.  Out-patient parenteral antimicrobial therapy--a viable option for the management of cutaneous leishmaniasis. , 1999, QJM : monthly journal of the Association of Physicians.

[3]  D. Fisher,et al.  A cost analysis of Outpatient Parenteral Antibiotic Therapy (OPAT): an Asian perspective. , 2009, International journal of antimicrobial agents.

[4]  G. Foti,et al.  Outpatient Parenteral Antibiotic Therapy for Bone and Joint Infections: An Italian Multicenter Study , 2007, Journal of chemotherapy.

[5]  R. Seaton,et al.  Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone. , 2005, The Journal of antimicrobial chemotherapy.

[6]  R. Seaton,et al.  Management of suspected Lyme borreliosis: experience from an outpatient parenteral antibiotic therapy service. , 2013, QJM : monthly journal of the Association of Physicians.

[7]  R. Rucker,et al.  Outpatient intravenous medications in the management of cystic fibrosis. , 1974, Pediatrics.

[8]  P. Matthews,et al.  Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. , 2007, The Journal of antimicrobial chemotherapy.

[9]  H. Fraimow,et al.  Adverse effects of outpatient parenteral antibiotic therapy. , 1999, The American journal of medicine.

[10]  M. Bennie,et al.  Scottish Antimicrobial Prescribing Group (SAPG): development and impact of the Scottish National Antimicrobial Stewardship Programme. , 2011, International journal of antimicrobial agents.

[11]  R. Seaton,et al.  Outpatient parenteral antimicrobial therapy (OPAT) in a teaching hospital-based practice: a retrospective cohort study describing experience and evolution over 10 years. , 2012, International journal of antimicrobial agents.

[12]  H. Boucher,et al.  Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy , 2009, The Journal of antimicrobial chemotherapy.

[13]  Donald R Graham,et al.  Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  D. Nathwani,et al.  Out-patient and home-parenteral antibiotic therapy (OHPAT): evaluation of the impact of one year's experience in Tayside. , 1999, Health bulletin.

[15]  K. Lindfield,et al.  Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry , 2008, International journal of clinical practice.

[16]  H. Wickens,et al.  Establishment of an outpatient and home parenteral antimicrobial therapy service at a London teaching hospital: a case series. , 2009, The Journal of antimicrobial chemotherapy.

[17]  Jason E. Bowling,et al.  Outpatient Parenteral Antimicrobial Therapy , 2013 .

[18]  J. Gatell,et al.  Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. , 2011, Enfermedades infecciosas y microbiologia clinica.

[19]  C. Marra,et al.  Cost Analysis of an Adult Outpatient Parenteral Antibiotic Therapy (OPAT) Programme , 2000, PharmacoEconomics.

[20]  Hospital in the home: a randomised controlled trial. , 1998, The Medical journal of Australia.

[21]  D. Nathwani The Management of Skin and Soft Tissue Infections: Outpatient Parenteral Antibiotic Therapy in the United Kingdom , 2000, Chemotherapy.

[22]  A. Upton,et al.  Outpatient Parenteral Antimicrobial Therapy (OPAT): a review of experience at Auckland Hospital. , 2004, The New Zealand medical journal.

[23]  J. Loeffler,et al.  Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience. , 2013, International journal of antimicrobial agents.

[24]  A. Tice Experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA , 1995, European Journal of Clinical Microbiology and Infectious Diseases.

[25]  D. Nathwani,et al.  Point prevalence survey of antibiotic use in Scottish hospitals utilising the Glasgow Antimicrobial Audit Tool (GAAT). , 2007, International journal of antimicrobial agents.

[26]  B. Howden,et al.  5: Hospital‐in‐the‐home treatment of infectious diseases , 2002, The Medical journal of Australia.

[27]  T. Peto,et al.  Safe intravenous antibiotic therapy at home: experience of a UK based programme. , 1996, The Journal of antimicrobial chemotherapy.

[28]  R. Seaton,et al.  Enteric fever in returning travellers: role of outpatient parenteral antibiotic therapy. , 2012, The Journal of infection.

[29]  R. Seaton,et al.  Outpatient parenteral antimicrobial therapy with ceftriaxone, a review , 2012, International Journal of Clinical Pharmacy.

[30]  R. Seaton,et al.  Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis , 2013, The Journal of antimicrobial chemotherapy.

[31]  Hien H. Nguyen Hospitalist to home: outpatient parenteral antimicrobial therapy at an academic center. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  S. Chambers,et al.  Primary care Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital , 2004 .

[33]  C. Weir,et al.  Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. , 2011, International journal of antimicrobial agents.

[34]  A. Tice,et al.  Outpatient parenteral antimicrobial therapy for central nervous system infections. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  Practice Guidelines for Outpatient Parenteral Antimicrobial Therapy , 2004 .

[36]  K. Bowker,et al.  Use of meropenem 3 g once daily for outpatient treatment of infective exacerbations of bronchiectasis. , 2000, The Journal of antimicrobial chemotherapy.

[37]  P. Tambyah,et al.  Outpatient parenteral antibiotic therapy in Singapore. , 2006, International journal of antimicrobial agents.

[38]  Self-administration of outpatient parenteral antibiotic therapy and risk of catheter-related adverse events: a retrospective cohort study , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[39]  D. Nathwani,et al.  Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. , 2012, The Journal of antimicrobial chemotherapy.

[40]  H. Doll,et al.  Admission avoidance hospital at home. , 2008, The Cochrane database of systematic reviews.

[41]  A. Tice Pharmacoeconomic Considerations in the Ambulatory Use of Parenteral Cephalosporins , 2012, Drugs.

[42]  T. Winstanley,et al.  Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms. , 2010, The Journal of antimicrobial chemotherapy.

[43]  G. Woods,et al.  Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. , 2004, The Journal of infection.

[44]  S. Dixon,et al.  Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. , 2009, The Journal of antimicrobial chemotherapy.

[45]  R. Seaton,et al.  Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. , 2009, The Journal of antimicrobial chemotherapy.